AU Patent

AU2022291429B2 — Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Assigned to Astex Therapeutics Ltd · Expires 2025-04-03 · 1y expired

What this patent protects

The invention relates to pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl) N'-(1-methylethyl)-N-[3(1-methyl-iH-pyrazol-4-yl)quinoxalin-6- yl]ethane-1,2-diamine, or a 5 pharmaceutically acceptable salt thereof or a solvate thereof; to processes for the preparation o…

USPTO Abstract

The invention relates to pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl) N'-(1-methylethyl)-N-[3(1-methyl-iH-pyrazol-4-yl)quinoxalin-6- yl]ethane-1,2-diamine, or a 5 pharmaceutically acceptable salt thereof or a solvate thereof; to processes for the preparation of said compositions and to the use of said compositions for the manufacture of a medicament for the prophylaxis of or the treatment, in particular the treatment, of diseases, e.g. cancer.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022291429B2
Jurisdiction
AU
Classification
—
Expires
2025-04-03
Drug substance claim
No
Drug product claim
No
Assignee
Astex Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.